Empagliflozin

Generic Name
Empagliflozin
Brand Names
Glyxambi, Jardiance, Synjardy, Trijardy
Drug Type
Small Molecule
Chemical Formula
C23H27ClO7
CAS Number
864070-44-0
Unique Ingredient Identifier
HDC1R2M35U
Background

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...

Indication

Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...

Associated Conditions
Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
Monotherapy
Clinical Trials
Related News

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

First Posted Date
2016-05-11
Last Posted Date
2018-02-15
Lead Sponsor
Northwell Health
Registration Number
NCT02768220

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Empagliflozin
Drug: Linagliptin
First Posted Date
2016-05-02
Last Posted Date
2017-11-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02758171
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

SGLT2 Inhibition and Left Ventricular Mass

Phase 4
Terminated
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Empagliflozin
Drug: Glimepiride
First Posted Date
2016-04-05
Last Posted Date
2019-03-22
Lead Sponsor
Hannover Medical School
Target Recruit Count
7
Registration Number
NCT02728453
Locations
🇩🇪

Hannover Medical School, Hannover, Germany

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Not Applicable
Completed
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Drug: Empagliflozin
First Posted Date
2016-02-19
Last Posted Date
2019-08-15
Lead Sponsor
Medanta, The Medicity, India
Target Recruit Count
100
Registration Number
NCT02686476
Locations
🇮🇳

Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon, Haryana, India

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

First Posted Date
2015-12-22
Last Posted Date
2023-06-05
Lead Sponsor
The Deutsche Diabetes Forschungsgesellschaft e.V.
Target Recruit Count
84
Registration Number
NCT02637973
Locations
🇩🇪

German Diabetes Center, Dusseldorf, Germany

🇩🇪

University Clinic Tübingen, Tübingen, Germany

🇩🇪

Charite Universitaetsmedizin Berlin, Berlin, Germany

and more 2 locations

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

First Posted Date
2015-12-17
Last Posted Date
2020-07-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
31
Registration Number
NCT02632747
Locations
🇨🇦

Toronto General Hospital, Toronto, Ontario, Canada

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Empagliflozin
Drug: Placebo
First Posted Date
2015-10-28
Last Posted Date
2019-03-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
269
Registration Number
NCT02589639
Locations
🇯🇵

Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan

🇯🇵

North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan

🇯🇵

Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan

and more 45 locations

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: Empagliflozin
Drug: Placebo
First Posted Date
2015-10-20
Last Posted Date
2018-11-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
977
Registration Number
NCT02580591
Locations
🇺🇸

International Research Associates, LLC, Hialeah, Florida, United States

🇺🇸

University of Maryland School of Medicine, Baltimore, Maryland, United States

🇺🇸

Sestron Clinical Research, Marietta, Georgia, United States

and more 186 locations

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Empagliflozin
Drug: Metformin
First Posted Date
2015-10-16
Last Posted Date
2016-11-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02577315
Locations
🇷🇺

1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Phase 3
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: Placebo
Drug: Empagliflozin
First Posted Date
2015-06-15
Last Posted Date
2018-05-15
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
74
Registration Number
NCT02471963
Locations
🇩🇪

University of Erlangen-Nuremberg, Erlangen, Bavaria, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy